American Medical Association

SHERPA: White

People

  1. Scher
    Scher
  2. Motzer
    Motzer
  3. Berger
    Berger
  4. Morris
    Morris
  5. Solit
    Solit
  6. Ladanyi
    Ladanyi
  7. Rosenberg
    Rosenberg
  8. Offit
    Offit
  9. Schultz
    Schultz
  10. Stadler
    Stadler

Groups

  1. Department of Medicine (48)
  2. Genitourinary Oncology Service (48)
  3. Solid Tumor Oncology Division (48)
  4. Epidemiology and Biostatistics (13)
  5. GSK Faculty (12)
  6. Department of Pathology and Laboratory Medicine (11)
  7. Human Oncology and Pathogenesis Program (11)
  8. Population Sciences Research Program (11)
  9. Tow Center for Developmental Oncology (TCDO) (10)
  10. Biostatistics Service (9)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (39)
  2. Correspondence (3)
  3. Review (3)
  4. Research Letter (2)
  5. Editorial (1)
Groups
  1. Department of Medicine (48)
  2. Genitourinary Oncology Service (48)
  3. Solid Tumor Oncology Division (48)
  4. Epidemiology and Biostatistics (13)
  5. GSK Faculty (12)
  6. Department of Pathology and Laboratory Medicine (11)

More Groups

People
  1. Howard Scher (14)
  2. Robert Motzer (10)
  3. Michael Berger (9)
  4. David Solit (8)
  5. Michael Morris (8)
  6. Marc Ladanyi (7)

More People

Years
  1. 2025 (2)
  2. 2024 (4)
  3. 2023 (3)
  4. 2022 (2)
  5. 2021 (3)
  6. 2020 (4)

More Years

Publications
  1. JAMA Oncology (38)
  2. JAMA - Journal of the American Medical Association (7)
  3. JAMA Network Open (1)
  4. JAMA Ophthalmology (1)
  5. JAMA Surgery (1)

Results (48)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: A secondary analysis of a randomized clinical trial
    Journal Article

    Armstrong, A. J.; Anand, A.; Edenbrandt, L.; Bondesson, E.; Bjartell, A.; Widmark, A.; Sternberg, C. N.; Pili, R.; Tuvesson, H.; Nordle, O.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: The PREVAIL randomized clinical trial
    Journal Article

    Rathkopf, D. E.; Beer, T. M.; Loriot, Y.; Higano, C. S.; Armstrong, A. J.; Sternberg, C. N.; De Bono, J. S.; Tombal, B.; Parli, T.; Bhattacharya, S.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: The UPWARD study
    Journal Article

    Slovin, S.; Clark, W.; Carles, J.; Krivoshik, A.; Park, J. W.; Wang, F.; George, D.
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer
    Journal Article

    Hearn, J. W. D.; Xie, W.; Nakabayashi, M.; Almassi, N.; Reichard, C. A.; Pomerantz, M.; Kantoff, P. W.; Sharifi, N.
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer
    Journal Article

    Fox, J. J.; Gavane, S. C.; Blanc-Autran, E.; Nehmeh, S.; Gonen, M.; Beattie, B.; Vargas, H. A.; Schoder, H.; Humm, J. L.; Fine, S. W.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Prognostic and predictive value of a breast cancer expression signature in localized prostate cancer
    Journal Article

    Abida, W.; Scher, H. I.
    JAMA Oncology (2017)

    Fulltext@MSK | Save
  • Perioperative management of localized kidney cancer: Watching and waiting
    Journal Article

    Voss, M. H.; Motzer, R. J.
    JAMA Oncology (2017)

    Fulltext@MSK | Save
  • Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing
    Journal Article

    Mandelker, D.; Zhang, L.; Kemel, Y.; Stadler, Z. K.; Joseph, V.; Zehir, A.; Pradhan, N.; Arnold, A.; Walsh, M. F.; Li, Y.; more...
    JAMA - Journal of the American Medical Association (2017)

    Fulltext@MSK | Save
  • Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment
    Journal Article

    Basch, E.; Deal, A. M.; Dueck, A. C.; Scher, H. I.; Kris, M. G.; Hudis, C.; Schrag, D.
    JAMA - Journal of the American Medical Association (2017)

    Fulltext@MSK | Save
  • Surrogate end points for all-cause mortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy vs radiation therapy plus androgen deprivation therapy: A secondary analysis of a randomized clinical trial
    Journal Article

    Royce, T. J.; Chen, M. H.; Wu, J.; Loffredo, M.; Renshaw, A. A.; Kantoff, P. W.; D'Amico, A. V.
    JAMA Oncology (2017)

    Fulltext@MSK | Save